UBS Maintains Neutral on Oscar Health, Raises Price Target to $26
UBS analyst Jonathan Yong maintains Oscar Health (NYSE:OSCR) with a Neutral and raises the price target from $20 to $26.
Read original at benzingaStocks · News reference
Wells Fargo analyst Stephen Baxter maintains Oscar Health (NYSE:OSCR) with a Equal-Weight and raises the price target from $20 to $27.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
UBS analyst Jonathan Yong maintains Oscar Health (NYSE:OSCR) with a Neutral and raises the price target from $20 to $26.
Read original at benzingaOscar Health (OSCR) beat Q2 earnings with $4.88B revenue, but shares fell on expected ACA membership churn in H2. Read more.
Read original at benzinga